Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.79 |
| ▸ | CTSD | P07339 | 10/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.54 |
| ▸ | CTSE | P14091 | 1/20 | 0.50 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL2277786 | 0.94 | BACE1 (0.71) | BACE1CTSDKCNH2CTSEBACE2 | |
| SCHEMBL7867664 | 0.89 | BACE1 (1.00) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL2283288 | 0.88 | BACE1 (0.71) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL2283282 | 0.88 | BACE1 (0.71) | BACE1CTSDKCNH2BACE2 | |
| SCHEMBL7871915 | 0.88 | BACE1 (0.73) | BACE1CTSDKCNH2CTSEBACE2 | |
| SCHEMBL2282094 | 0.87 | BACE1 (0.66) | BACE1CTSDKCNH2CTSEBACE2 | |
| SCHEMBL2282086 | 0.87 | BACE1 (0.66) | BACE1CTSDKCNH2CTSEBACE2 | |
| SCHEMBL7863102 | 0.87 | BACE1 (0.79) | BACE1CTSDKCNH2 | |
| SCHEMBL7865295 | 0.86 | BACE1 (0.79) | BACE1CTSDKCNH2CTSEBACE2 | |
| Formic Acid SCHEMBL2282842 | 0.84 | BACE1 (0.64) | BACE1CTSDKCNH2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| WO-2009103626-A1 | 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 721/4885KCNH2 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.